Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19)
Aim. To study the effectiveness of Kolofort® (affinally purified antibodies to tumor necrosis factor α, to the brain-specific protein S-100 and to histamine) in patients with various variants of irritable bowel syndrome (IBS) that developed after a new coronavirus infection (COVID-19).Materials and...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2022-05-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/716 |
| _version_ | 1797245183573622784 |
|---|---|
| author | R. G. Myazin |
| author_facet | R. G. Myazin |
| author_sort | R. G. Myazin |
| collection | DOAJ |
| description | Aim. To study the effectiveness of Kolofort® (affinally purified antibodies to tumor necrosis factor α, to the brain-specific protein S-100 and to histamine) in patients with various variants of irritable bowel syndrome (IBS) that developed after a new coronavirus infection (COVID-19).Materials and methods. Clinical and laboratory data of 32 patients with IBS who had a history of COVID-19 pneumonia were analyzed. Course therapy with Kolofort® is prescribed according to the standard scheme for 3 months. Before and after treatment, the dynamics of the symptoms of IBS was assessed according to the questionnaire, the dynamics of anxiety was assessed according to the Hamilton scale.Results. There were a statistically significant decrease in the severity of IBS symptoms (normalization of the consistency of the stool, cessation of flatulence, a decrease in abdominal pain; p < 0.05) and a decrease in anxiety after the end of treatment.Conclusions. Kolofort® may be effective in eliminating the symptoms of post-infectious IBS and anxiety that developed after COVID-19. |
| first_indexed | 2024-03-08T09:20:50Z |
| format | Article |
| id | doaj.art-46479a9a59f94386af91f62c1439bd9d |
| institution | Directory Open Access Journal |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| last_indexed | 2024-04-24T19:22:51Z |
| publishDate | 2022-05-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj.art-46479a9a59f94386af91f62c1439bd9d2024-03-25T16:53:10ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732022-05-01321414510.22416/1382-4376-2022-32-1-41-45461Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19)R. G. Myazin0Volgograd State Medical University of the Ministry of Health of the Russian FederationAim. To study the effectiveness of Kolofort® (affinally purified antibodies to tumor necrosis factor α, to the brain-specific protein S-100 and to histamine) in patients with various variants of irritable bowel syndrome (IBS) that developed after a new coronavirus infection (COVID-19).Materials and methods. Clinical and laboratory data of 32 patients with IBS who had a history of COVID-19 pneumonia were analyzed. Course therapy with Kolofort® is prescribed according to the standard scheme for 3 months. Before and after treatment, the dynamics of the symptoms of IBS was assessed according to the questionnaire, the dynamics of anxiety was assessed according to the Hamilton scale.Results. There were a statistically significant decrease in the severity of IBS symptoms (normalization of the consistency of the stool, cessation of flatulence, a decrease in abdominal pain; p < 0.05) and a decrease in anxiety after the end of treatment.Conclusions. Kolofort® may be effective in eliminating the symptoms of post-infectious IBS and anxiety that developed after COVID-19.https://www.gastro-j.ru/jour/article/view/716coronavirus infectionirritable bowel syndromediagnosistreatmentkolofort® |
| spellingShingle | R. G. Myazin Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19) Российский журнал гастроэнтерологии, гепатологии, колопроктологии coronavirus infection irritable bowel syndrome diagnosis treatment kolofort® |
| title | Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19) |
| title_full | Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19) |
| title_fullStr | Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19) |
| title_full_unstemmed | Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19) |
| title_short | Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19) |
| title_sort | experience in the treatment of irritable bowel syndrome developed after a new coronavirus infection covid 19 |
| topic | coronavirus infection irritable bowel syndrome diagnosis treatment kolofort® |
| url | https://www.gastro-j.ru/jour/article/view/716 |
| work_keys_str_mv | AT rgmyazin experienceinthetreatmentofirritablebowelsyndromedevelopedafteranewcoronavirusinfectioncovid19 |